VICTOR: A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

Sponsor
Astellas Pharma Inc (Industry)
Overall Status
Completed
CT.gov ID
NCT00333112
Collaborator
(none)
398
74
2
8
5.4
0.7

Study Details

Study Description

Brief Summary

A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

A 2 arm study ( 1 Active, 1 Placebo) to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men

Study Design

Study Type:
Interventional
Actual Enrollment :
398 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare® (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR: VESIcare® In Combination With Tamsulosin in OAB Residual Symptoms
Study Start Date :
May 1, 2006
Actual Primary Completion Date :
Jan 1, 2007
Actual Study Completion Date :
Jan 1, 2007

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

Drug: solifenacin succinate
Oral
Other Names:
  • Vesicare®
  • YM905
  • Drug: tamsulosin
    oral

    Placebo Comparator: 2

    Drug: tamsulosin
    oral

    Drug: placebo
    oral

    Outcome Measures

    Primary Outcome Measures

    1. Change in micturitions per 24 hours from baseline to end of treatment [18 weeks]

    Secondary Outcome Measures

    1. Change in urgency episodes per 24 hours from baseline to end of treatment [18 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    45 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Symptoms of Overactive Bladder (OAB)
    Exclusion Criteria:
    • Current use of antimuscarinic therapy

    • Evidence of a urinary tract infection

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Birmingham Alabama United States 35209
    2 Phoenix Arizona United States 85050
    3 Tuscon Arizona United States 85712
    4 Atherton California United States 94027
    5 Beverly Hills California United States 90211
    6 Buena Park California United States 90320
    7 Buena California United States 90620
    8 Carmichael California United States 95608
    9 Culver City California United States 90232
    10 Fresno California United States 93720
    11 Mission Hills California United States 92084
    12 Modesto California United States 95350
    13 Orange California United States 92869
    14 San Bernardino California United States 92404
    15 San Diego California United States 92108
    16 Torrance California United States 90505
    17 Aurora Colorado United States 80012
    18 Denver Colorado United States 80210
    19 Wheat Ridge Colorado United States 80033
    20 Danbury Connecticut United States 06708
    21 Clearwater Florida United States 33761
    22 Daytona Beach Florida United States 32114
    23 Fort Myers Florida United States 33908
    24 New Port Richey Florida United States 34652
    25 Orlando Florida United States 32803
    26 Orlando Florida United States 32806
    27 Pembroke Pines Florida United States 33027
    28 Pembroke Pines Florida United States 33028
    29 Tallahassee Florida United States 32308
    30 Wellington Florida United States 33414
    31 Atlanta Georgia United States 30342
    32 Blue Ridge Georgia United States 30513
    33 Marietta Georgia United States 30060
    34 Roswell Georgia United States 30076
    35 Sandy Springs Georgia United States 30328
    36 Snellville Georgia United States 30078
    37 Coeur d'Alene Idaho United States 83814
    38 Evansville Indiana United States 47714
    39 Wichita Kansas United States 67207
    40 Shreveport Louisiana United States 71106
    41 Boston Massachusetts United States 02115
    42 Watertown Massachusetts United States 02472
    43 Grand Rapids Michigan United States 49544
    44 Jackson Mississippi United States 39202
    45 West Orange New Jersey United States 07052
    46 Endwell New York United States 13760
    47 Garden City New York United States 11530
    48 New York New York United States 10016
    49 New York New York United States 10021
    50 Orchard Park New York United States 14127
    51 Poughkeepsie New York United States 12601
    52 Rochester New York United States 14642
    53 Concord North Carolina United States 28025
    54 Hickory North Carolina United States 28601
    55 Winston Salem North Carolina United States 27103
    56 Cincinnati Ohio United States 45212
    57 Cincinnati Ohio United States 45249
    58 Bethany Oklahoma United States 73008
    59 Norman Oklahoma United States 73071
    60 Springfield Oregon United States 97477
    61 Bala Cynwyd Pennsylvania United States 19004
    62 Bensalem Pennsylvania United States 19020
    63 Camp Hill Pennsylvania United States 17011
    64 Lancaster Pennsylvania United States 17604
    65 Uniontown Pennsylvania United States 15401
    66 Mt. Pleasant South Carolina United States 29464
    67 Simpsonville South Carolina United States 29681
    68 Nashville Tennessee United States 37203
    69 Houston Texas United States 77024
    70 Ogden Utah United States 84403
    71 Salt Lake City Utah United States 84121
    72 Virginia Beach Virginia United States 23454
    73 Mountain Lake Terrace Washington United States 98043
    74 Spokane Washington United States 99202

    Sponsors and Collaborators

    • Astellas Pharma Inc

    Investigators

    • Study Director: Astellas US Medical Information, Astellas Pharma US, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Astellas Pharma Inc
    ClinicalTrials.gov Identifier:
    NCT00333112
    Other Study ID Numbers:
    • 905-UC-008
    First Posted:
    Jun 2, 2006
    Last Update Posted:
    Sep 18, 2014
    Last Verified:
    Sep 1, 2014

    Study Results

    No Results Posted as of Sep 18, 2014